Condition: Melanoma · Lung Cancer · Renal Cancer · Sponsor: Hospices Civils de Lyon
The ipilimumab and nivolumab combination is now part of the standard of care for the treatment of melanoma, renal and lung cancer patients. Grade 3/4 adverse events (AEs) occur in 30 to 60% of patients included in clinical trials. Grade 3/4 AEs are more frequently observed (50-60% of patients) in melanoma because ipilimumab is administrated at 3mg/kg in this population. Among these AEs, early detection of immune related AEs is critical to an adequate medical management. In this context, dedicated tools for remote monitoring of these patients are crucial. The investigators developed within the Immucare consortium a simplified medical questionnaire which is addressed weekly to the patients. This questionnaire along with an algorithm gives to the clinician regular feedback on their patients' general symptoms. The investigators herein want to evaluate in a randomized prospective trial the efficacy of this remote monitoring to reduce the time between the start of AE and the reporting to the medical team, which could lead to detect and treat earlier AEs induced by nivolumab and ipilimumab in the melanoma, lung and renal cancer patients' population.
This description comes directly from the study's public registry record.
Stéphane DALLE · 0478861679 · stephane.dalle@chu-lyon.fr
Aurélie RABIER · 0478861679 · aurelie.rabier@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| Groupement hospitalier Est - Multidisciplinary oncological platform | Bron, France | Not Yet Recruiting |
| Hôpital Louis Pradel - Department of Pneumology | Bron, France | Not Yet Recruiting |
| University hospital of Grenoble Alpes - Department of dermatology | Grenoble, France | Not Yet Recruiting |
| University hospital of Grenoble Alpes - Department of Medical Oncology | Grenoble, France | Not Yet Recruiting |
| Hôpital de la Croix Rousse - Department of Pneumology | Lyon, France | Not Yet Recruiting |
| Hôpital Edouard Herriot - Department of urology | Lyon, France | Terminated |
| Centre Hospitalier Lyon Sud - Department of Medical Oncology | Pierre-Bénite, France | Recruiting |
| Hôpital Lyon Sud - Department of Dermatology, HCL-Cancer Institute | Pierre-Bénite, France | Recruiting |
| Hôpital Lyon Sud - Department of pneumology,Thoracic oncology | Pierre-Bénite, France | Recruiting |
| University hospital of Saint-Etienne - Department of dermatology | Saint-Etienne, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04605146